MORE►
biotech
The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
NanOlogy Names CEO as Its Tumor-Targeted Cancer Drugs Near Key Regulatory Milestones
by Sandra Engelland | Dec 30, 2025
The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
by Maddie Preston |
Dec 23, 2025
A new satellite campus is adding hands-on training, lab capacity and startup support to Dallas’ growing life sciences ecosystem.
MORE►
by Quincy Preston |
Nov 5, 2025
Cait Brumme says the event at Dallas' Pegasus Park on Nov. 6 will explore the technologies and economic forces defining the future for entrepreneurs and innovators.
MORE►
by Quincy Preston |
Nov 4, 2025
The de-extinction startup is adding more than two decades of commercial cloning expertise to its portfolio with its first acquisition.
Days before the announcement, CEO Ben Lamm laid out his playbook at Venture Dallas 2025: run toward critics, treat promises to middle-America classrooms as seriously as commitments to investors—and spin out businesses worth more than $100 million.
MORE►
[Image: Black_Kira/istockphoto]
Lantern Pharma Preps 2026 Trial for Rare Pediatric Brain Cancer After FDA Guidance
by Quincy Preston | Oct 14, 2025
The North Texas biotech, which uses AI to accelerate cancer drug development, received FDA feedback to advance a new clinical study targeting a rare childhood brain tumor.
MORE►
by Maddie Preston |
Sep 27, 2025
The UTD team’s approach adapts a chip-security technique to biology. The breakthrough gives biotech companies a new way to prevent costly misidentification and protect intellectual property.
MORE►
by Glenn Hunter |
Sep 24, 2025
At Dallas’ iC3 Summit, leaders from Texas and across the U.S. pointed to AI, new state initiatives like Proposition 14, and potential federal reforms as keys to speeding innovation and keeping America competitive in life sciences.
MORE►
by Lance Murray |
Aug 28, 2025
The Pittsburgh-headquartered nonprofit's executive director, Dallas-based Gina Ford, takes up the newly created top post of the organization, which empowers women across biotech, pharma, and life sciences to lead, engage, and grow at every career stage.
MORE►
BioLabs exterior view at Pegasus Park. [Photo: BioLabs at Pegasus Park]
CAGE Bio Relocates Fort Worth Office to BioLabs at Pegasus Park in Dallas
by David Seeley | Jul 15, 2025
The California-based clinical-stage biotech startup is developing therapies to treat serious immunological diseases like atopic dermatitis and vitiligo.
MORE►
![The South Island giant moa towered over New Zealand's forests for millions of years before becoming extinct within a century of Polynesian settlement around 1400 CE. Colossal Biosciences plans to resurrect the 500-pound birds using ancient DNA extracted from cave deposits and artificial egg technology. [Source image: Colossal Biosciences]](https://s24806.pcdn.co/wp-content/uploads/2025/07/Colossal-Moa-360x203.jpg)
by Quincy Preston |
Jul 9, 2025
The Dallas decacorn is scaling its de-extinction pipeline with indigenous leadership, a New Zealand subsidiary, and economic models for species preservation, including ecotourism opportunities. Filmmaker Sir Peter Jackson helped connect the collaborators, Colossal CEO Ben Lamm says.
MORE►
by Lance Murray |
Jun 5, 2025
Co-founded by Chief Scientific Advisor Daniel J. Siegwart of UT Southwestern and CEO RA Session II, Signify Bio said it harnesses the human body for the production of in situ protein therapeutics. The round was led by Actium Group with participation from the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, Eli Lilly and Company, and BrightEdge, the American Cancer Society's VC arm.
MORE►
by Lance Murray |
May 8, 2025
Eric Matthews will provide strategic leadership to biopharma business development, and through his executive leadership, support Caris' expanding portfolio of biopharma partnerships, the company said.
MORE►
David Halbert, founder, chairman, and CEO of Caris Life Sciences. [Courtesy: Caris]
Caris Life Sciences Raises $168M in Private Capital to Expand Platform
by Lance Murray | Apr 8, 2025
With the new funding, Caris said it has raised $1.86 billion in capital since 2018. Caris will use the raise to bring its science and technologies "to as many patients as possible and further our goal of revolutionizing precision medicine," Founder and CEO David Halbert said.
MORE►
by Quincy Preston |
Apr 7, 2025
“Game of Thrones” made them famous, but the prehistoric dire wolves were real—and, according to Colossal Biosciences, have now returned after 12,500 years in what it calls the world’s first successful de-extinction. The work goes beyond headlines: It could change how we save endangered species.
Meet Romulus, Remus, and Khaleesi in a video—and hear dire wolf howls for the first time in more than 12 millennia.
MORE►
by Nicole Ward, DRC Data Journalist |
Mar 27, 2025
Eido Bio’s three co-founders are taking on menopause, research gaps, and a market where women’s health “sort of starts and stops with birth control.” The biotech startup is raising a Series A to launch clinical trials for a menopause treatment—and help shift the science toward women.
MORE►
by Quincy Preston |
Jan 15, 2025
Best known for its moonshot mission to revive the woolly mammoth, Colossal Biosciences has secured $200 million in Series C funding led by TWG Global. The world's first de-extinction company, founded in 2021 by entrepreneur Ben Lamm and renowned Harvard geneticist George Church, Colossal Biosciences is working to restore Earth's lost biodiversity, "making science fiction into science fact."
MORE►
